Taking a “Development-by-Design” Approach to Cell Therapies

June 15, 2015

Agnes Shanley is senior editor of BioPharm International.

BioPharm International, BioPharm International-06-15-2015, Volume 2015 eBook, Issue 1

Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.

Cell therapies, both autologous and allogeneic, have come a long way in just a few years. Failures, often in clinical stages, have been traced to problems with manufacturing and failure to understand process requirements earlier in the development process.

Download

Taking a “Development-by-Design” Approach to Cell Therapies

Agnes Shanley

VIVEbiotech to Expand Facilities for Lentiviral-Vector Manufacturing

Avid Bioservices Expands Biologics Manufacturing Capacity

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience